Sun Pharmaceutical completed the acquisition of Checkpoint Therapeutics for $355m.

Sun Pharmaceutical, an Indian multinational pharmaceutical company, completed the acquisition of Checkpoint Therapeutics, a commercial-stage immunotherapy and targeted oncology company, for $355m. "This acquisition exemplifies Sun Pharma's commitment to supporting patients and growing its innovative therapies business. By adding UNLOXCYT™, we will be able to leverage our leadership in the onco-derm space to help patients access an important treatment option while growing our product portfolio," Dilip Shanghvi, Sun Pharma Chairman & Managing Director.